[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Mendler JH, Friedberg JW: Salvage therapy in Hodgkin's lymphoma. Oncologist; 2009 Apr;14(4):425-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage therapy in Hodgkin's lymphoma.
  • Hodgkin's lymphoma (HL) is a commonly cured malignancy.
  • Unfortunately, patients who are refractory to or relapse after first-line treatment pose a significant therapeutic challenge.
  • There is evidence that these patients are best treated with an approach involving salvage chemotherapy followed by high-dose chemotherapy and autologous stem cell transplant (HDCT/ASCT).
  • For those relapsing after HDCT/ASCT, there exists a range of therapeutic options, including further salvage chemotherapy, reduced-intensity allogeneic transplantation, monoclonal antibody therapy, and novel agents.
  • All patients in this category should be considered for enrollment in clinical trials.
  • Specifically, the efficacy of various salvage chemotherapy regimens, the risk factors influencing outcome with HDCT/ASCT, and the results with alternative transplant approaches, monoclonal antibody therapies, and novel agents are addressed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / therapy. Salvage Therapy / methods
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Chemotherapy, Adjuvant / methods. Clinical Trials as Topic. Drug Resistance, Neoplasm. Humans. Immunologic Factors / administration & dosage. Platinum Compounds / administration & dosage. Radiotherapy, Adjuvant / methods. Randomized Controlled Trials as Topic. Recurrence. Risk Factors. Stem Cell Transplantation / methods. Transplantation, Homologous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19342476.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Immunologic Factors; 0 / Platinum Compounds
  • [Number-of-references] 59
  •  go-up   go-down


2. Intragumtornchai T, Prayoonwiwat W, Numbenjapon T, Assawametha N, O'Charoen R, Swasdikul D: CHOP versus CHOP plus ESHAP and high-dose therapy with autologous peripheral blood progenitor cell transplantation for high-intermediate-risk and high-risk aggressive non-Hodgkin's lymphoma. Clin Lymphoma; 2000 Dec;1(3):219-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CHOP versus CHOP plus ESHAP and high-dose therapy with autologous peripheral blood progenitor cell transplantation for high-intermediate-risk and high-risk aggressive non-Hodgkin's lymphoma.
  • The purpose of the study was to compare conventional cyclophosphamide/doxorubicin/vincristine/prednisolone (CHOP) chemotherapy with CHOP (3 courses) plus etoposide/methylprednisolone/high-dose cytarabine/cisplatin (ESHAP), high-dose therapy (HDT), and autologous peripheral blood progenitor cell transplantation (PBPCT) as front-line treatment for poor-prognosis aggressive non-Hodgkin's lymphoma (NHL).
  • Between May 1, 1995, and April 30, 1998, 58 patients, aged 15-55 years, newly diagnosed with poor-prognosis aggressive NHL (category F-H by the Working Formulation) were enrolled.
  • With a median follow-up duration of 39 months, the 4-year failure-free survival (FFS) was superior in the ESHAP/HDT group (38%, 95% CI: 18%-58% vs. 15%, 95% CI: 4%-32%) (P = 0.04).
  • The 4-year overall survival between the two treatment arms was comparable (51%, 95% CI: 28%-70% for ESHAP/HDT vs. 30%, 95% CI: 13%-48% for CHOP) (P = 0.25).
  • Treatment-related mortalities were not significantly different between both groups (17%, 95% CI: 5%-39% for ESHAP/HDT vs. 8%, 95% CI: 1%-26% for CHOP) (P = 0.41).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Hematopoietic Stem Cell Transplantation. Lymphoma, Non-Hodgkin / drug therapy. Methylprednisolone / therapeutic use. Prednisone / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Survival Rate. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11707834.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; VB0R961HZT / Prednisone; X4W7ZR7023 / Methylprednisolone; CHOP protocol; ESAP protocol
  •  go-up   go-down


3. Olivares Camacho JL, Cabrera V, Cabrera JI: [Hodgkin's lymphoma with thoracic column metastasis. A case report]. Acta Ortop Mex; 2008 Jan-Feb;22(1):62-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hodgkin's lymphoma with thoracic column metastasis. A case report].
  • [Transliterated title] Linfoma de Hodgkin con metástasis a columna torácica. Presentación de caso.
  • This 20 years old male patient with a history of Hodgkin's disease since 1996, stage II variety nodular sclerosis, was initially managed with radiotherapy and chemotherapy ending such treatment in January 1997, subsequently treated with interferon for one year, ending in January 1998, presented complete remission and was maintained in observation; in June 1999 started with thoracolumbar pain, weakness and diminished sensitivity on lower limbs, studies were conducted and diagnosed epidural tumor from levels T9 to T12, with important spinal cord compression; the patient was submitted to surgery and neurological recovery was complete.
  • [MeSH-major] Hodgkin Disease / complications. Hodgkin Disease / surgery. Spinal Neoplasms / secondary. Thoracic Vertebrae

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18672756.001).
  • [ISSN] 2306-4102
  • [Journal-full-title] Acta ortopédica mexicana
  • [ISO-abbreviation] Acta Ortop Mex
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


Advertisement
4. Kasamon YL, Wahl RL, Ziessman HA, Blackford AL, Goodman SN, Fidyk CA, Rogers KM, Bolaños-Meade J, Borowitz MJ, Ambinder RF, Jones RJ, Swinnen LJ: Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning. Biol Blood Marrow Transplant; 2009 Feb;15(2):242-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning.
  • In newly diagnosed aggressive non-Hodgkin lymphoma (NHL), a positive midtreatment fluorine-18 fluorodeoxyglucose positron emission tomography (PET) scan often carries a poor prognosis, with reported 2-year event-free survival (EFS) rates of 0% to 30% after standard therapy.
  • To determine the outcome of early treatment intensification for midtreatment PET-positive disease, a phase II trial of risk-adapted therapy was conducted.
  • Fifty-nine newly diagnosed patients, 98% with B cell lymphoma, had PET/CT performed after 2 or 3 cycles of first-line chemotherapy.
  • Those with negative PET on semiquantitative visual interpretation completed standard therapy.
  • Those with positive PET received platinum-based salvage chemotherapy, high-dose therapy, and autologous stem cell transplantation (ASCT).
  • No association was found between the International Prognostic Index category and the midtreatment PET result.
  • The favorable outcome achieved here in historically poor-risk patients warrants further, more definitive investigation of treatment modification based on early PET scanning.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / therapy. Positron-Emission Tomography
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Fluorodeoxyglucose F18. Hematopoietic Stem Cell Transplantation. Humans. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / therapy. Male. Middle Aged. Platinum Compounds / therapeutic use. Prognosis. Risk Assessment. Salvage Therapy / methods. Survival Analysis. Transplantation, Autologous. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Treat Rev. 2007 Jun;33(4):338-46 [17400393.001]
  • [Cites] Blood. 2007 Mar 1;109(5):1857-61 [17105812.001]
  • [Cites] Hematology. 2007 Oct;12(5):423-30 [17852456.001]
  • [Cites] Ann Oncol. 2009 Feb;20(2):309-18 [18842613.001]
  • [Cites] Haematologica. 2000 Jun;85(6):613-8 [10870118.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2472-9 [12011124.001]
  • [Cites] Ann Oncol. 2002 Sep;13(9):1356-63 [12196360.001]
  • [Cites] Blood. 2003 Jul 1;102(1):53-9 [12609836.001]
  • [Cites] Haematologica. 2003 Nov;88(11):1304-15 [14607760.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):277-85 [14722036.001]
  • [Cites] N Engl J Med. 2004 Mar 25;350(13):1287-95 [15044639.001]
  • [Cites] N Engl J Med. 1983 Dec 1;309(22):1347-53 [6355849.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1376-81 [15860666.001]
  • [Cites] Ann Oncol. 2005 Sep;16(9):1514-23 [15980161.001]
  • [Cites] Radiology. 2005 Dec;237(3):1038-45 [16304117.001]
  • [Cites] Cancer. 2006 Dec 1;107(11):2678-87 [17063502.001]
  • [Cites] Blood. 2007 Jan 15;109(2):486-91 [17003382.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):571-8 [17242397.001]
  • [Cites] Acad Radiol. 2007 Mar;14(3):330-9 [17307666.001]
  • [Cites] Nucl Med Commun. 2007 Oct;28(10):798-803 [17728610.001]
  • (PMID = 19167684.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA006973; United States / NCI NIH HHS / CA / P50 CA096888
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Platinum Compounds; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ NIHMS281891; NLM/ PMC4020440
  •  go-up   go-down


5. Belgaumi A, Al-Kofide AA, Khafaga Y, Joseph N, Jamil-Malik R, Siddiqui KS, Sabbah RS: Clinical characteristics and outcome of pediatric patients with stage IV Hodgkin lymphoma. Hematol Oncol Stem Cell Ther; 2009;2(1):278-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and outcome of pediatric patients with stage IV Hodgkin lymphoma.
  • BACKGROUND AND OBJECTIVES: While treatment outcomes for patients with Hodgkin lymphoma (HL) have improved remarkably, patients with disseminated disease still have a poorer outcome.
  • This single-institution report looks at characteristics and outcomes of this specific category.
  • Stage IV patients received chemotherapy (CT) alone (n = 55) or combined modality therapy (CMT) (n = 12).
  • On multivariate analysis, failure to achieve complete remission with CT was associated with a poorer outcome.
  • Slow responders may require novel and/or aggressive therapy to achieve complete remission.
  • [MeSH-major] Hodgkin Disease / pathology. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Child. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Neoplasm Staging. Radiotherapy. Retrospective Studies. Risk Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20063558.001).
  • [ISSN] 1658-3876
  • [Journal-full-title] Hematology/oncology and stem cell therapy
  • [ISO-abbreviation] Hematol Oncol Stem Cell Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


6. Gospodarowicz MK, Meyer RM: The management of patients with limited-stage classical Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program; 2006;:253-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The management of patients with limited-stage classical Hodgkin lymphoma.
  • The term limited-stage Hodgkin lymphoma refers to those patients with stage I-II disease and an absence of bulky disease.
  • Among those patients with classical Hodgkin lymphoma, approximately one-third of patients will fall into this category.
  • As long-term disease control can now be anticipated in more than 90% of these patients, management strategies must increasingly address the need to reduce the long-term treatment-related risks.
  • Current treatment options include use of combined modality therapy that includes an abbreviated course of chemotherapy and involved-field radiation or treatment with chemotherapy, currently consisting of ABVD, as a single modality.
  • The choice of treatment between these two options involves specific trade-offs that must balance issues of disease control against long-term risk of late effects.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17124069.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


7. Yahalom J: Favorable early-stage Hodgkin lymphoma. J Natl Compr Canc Netw; 2006 Mar;4(3):233-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favorable early-stage Hodgkin lymphoma.
  • The category of favorable early-stage Hodgkin lymphoma (HL) includes patients with Ann Arbor stages I or II disease with no bulky disease or B symptoms.
  • Indeed, effective treatments for this group of patients have been available for more than 4 decades.
  • However, treatment strategies have radically changed over the past 15 years and focus now on maintaining the high cure rate while reducing the risk of treatment-related long-term morbidity.
  • The optimal treatment is still evolving, and more recently, reduction in the total amount of chemotherapy and in radiation field and dose has shown excellent results.
  • Combined modality therapy is the preferred treatment for patients with classical favorable early-stage HL (nodular sclerosis or mixed cellularity histology).
  • Patients with early-stage lymphocyte predominance HL are highly curable using involved-field radiation therapy (IFRT) alone and do not require chemotherapy.
  • Classical favorable HL is also curable with radiotherapy alone or with chemotherapy alone, but larger fields and higher-dose radiation or longer chemotherapy is required compared with combined modality.
  • The freedom from treatment failure rate is significantly better with a combination of short chemotherapy and IFRT than with either chemotherapy or radiotherapy alone.
  • Although combined modality is the standard preferred treatment for favorable disease, radiation therapy alone or chemotherapy alone could be considered under special circumstances or as part of an investigational protocol.
  • [MeSH-major] Hodgkin Disease / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Humans. Neoplasm Staging. Radiotherapy. Survival Analysis

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16507270.001).
  • [ISSN] 1540-1405
  • [Journal-full-title] Journal of the National Comprehensive Cancer Network : JNCCN
  • [ISO-abbreviation] J Natl Compr Canc Netw
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 47
  •  go-up   go-down


8. Todeschini G, Secchi S, Morra E, Vitolo U, Orlandi E, Pasini F, Gallo E, Ambrosetti A, Tecchio C, Tarella C, Gabbas A, Gallamini A, Gargantini L, Pizzuti M, Fioritoni G, Gottin L, Rossi G, Lazzarino M, Menestrina F, Paulli M, Palestro M, Cabras MG, Di Vito F, Pizzolo G: Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer; 2004 Jan 26;90(2):372-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B.
  • The optimal treatment of primary mediastinal large B-cell lymphoma (PMLBCL) is still undefined.
  • In the absence of randomised studies, we retrospectively analysed: (a) the effectiveness of two chemotherapy regimens (CHOP vs MACOP-B/VACOP-B) in complete remission (CR) achievement and event-free survival (EFS) and (b) the role of mediastinal involved-field radiotherapy (IF-RT) as consolidation.
  • The two groups of patients were similar as regard to age, gender, presence of bulky mediastinal mass, pleural effusion, stage and international prognostic indexes category of risk.
  • The addition of IF-RT as consolidation improved the outcome, irrespectively of the type of chemotherapy (P=0.04).
  • At a multivariate analysis, achievement of CR (P<0.0001) and type of CT (MACOP-B/VACOP-B) retained the significance for OS (P=0.008) and EFS (P=0.03).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Mediastinal Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Leucovorin / administration & dosage. Male. Methotrexate / administration & dosage. Middle Aged. Prednisone / administration & dosage. Prognosis. Retrospective Studies. Risk Factors. Treatment Outcome. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1986 Jun;10(6):589-600 [3525372.001]
  • [Cites] Semin Oncol. 1999 Jun;26(3):251-8 [10375082.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1987;412(1):17-21 [2825402.001]
  • [Cites] Cancer. 1988 Nov 1;62(9):1893-8 [3167803.001]
  • [Cites] Am J Surg Pathol. 1989 Sep;13(9):730-9 [2788371.001]
  • [Cites] Am J Clin Oncol. 1989 Oct;12(5):425-9 [2801603.001]
  • [Cites] Leuk Lymphoma. 1999 Nov;35(5-6):537-44 [10609791.001]
  • [Cites] Haematologica. 2001 Feb;86(2):187-91 [11224489.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1855-64 [11251018.001]
  • [Cites] J Clin Oncol. 1990 May;8(5):804-8 [1692089.001]
  • [Cites] Cancer. 1991 May 15;67(10):2579-87 [2015557.001]
  • [Cites] Ann Oncol. 1991 Nov-Dec;2(10):733-7 [1724908.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1336-43 [8315431.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] J Clin Oncol. 1993 Dec;11(12):2306-13 [8246020.001]
  • [Cites] Br J Cancer. 1994 Mar;69(3):601-4 [8123496.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Hematol Oncol. 1994 Jul-Aug;12(4):175-84 [8001905.001]
  • [Cites] Br J Haematol. 1995 Apr;89(4):780-9 [7539625.001]
  • [Cites] Am J Surg Pathol. 1996 Jul;20(7):877-88 [8669537.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1646-53 [9193365.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):63-9 [9440724.001]
  • [Cites] Blood. 1998 Jan 15;91(2):717-23 [9427731.001]
  • [Cites] Ann Oncol. 1998 Sep;9(9):1027-9 [9818079.001]
  • [Cites] Haematologica. 2002 Dec;87(12):1258-64 [12495899.001]
  • [Cites] Cancer. 1982 Dec 1;50(11):2486-92 [7139540.001]
  • [Cites] Am J Clin Pathol. 1985 Jun;83(6):676-80 [3923821.001]
  • [Cites] Am J Surg Pathol. 1986 Mar;10(3):176-91 [3953939.001]
  • [Cites] Histopathology. 1986 Apr;10(4):379-90 [2423430.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):784-90 [10071267.001]
  • [Cites] Blood. 1987 Apr;69(4):1087-95 [3103712.001]
  • (PMID = 14735179.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol; MACOP-B protocol; VACOP-B protocol
  • [Other-IDs] NLM/ PMC2409547
  •  go-up   go-down


9. Shimazaki K, Ohshima K, Haraoka S, Suzumiya J, Nakamura N, Kikuchi M: Accessory cell tumour: a clinicopathological study of 16 aggressive tumours containing EBV-positive Hodgkin and Reed-Sternberg-like giant cells. Histopathology; 2002 Jan;40(1):12-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accessory cell tumour: a clinicopathological study of 16 aggressive tumours containing EBV-positive Hodgkin and Reed-Sternberg-like giant cells.
  • Functionally, these cells belong to the category of immune accessory cells involved in antigen presentation to B or T-lymphocytes.
  • In all cases, binucleated or multinucleated Hodgkin and Reed-Sternberg-like giant cells were encountered.
  • ISH-EBV yielded positive labelling in seven of 11 cases, of which five exhibited EBV only in Hodgkin and Reed-Sternberg-like giant cells.
  • Many tumours were very refractory to chemotherapy and radiation, with a few exceptions, and half of the cases classified initially as stage IV.
  • A short survival time, of 10 months or less, was observed in seven of 16 patients.
  • Our results suggest that EBV may potentially induce activation of accessory cells to form Hodgkin and Reed-Sternberg-like giant cells, which correspond with poor prognosis.
  • [MeSH-major] Dendritic Cells, Follicular / pathology. Herpesvirus 4, Human / isolation & purification. Lymph Nodes / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Reed-Sternberg Cells / pathology. Sarcoma / pathology

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11903594.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / RNA, Viral
  •  go-up   go-down


10. Babovic N, Jelic S, Jovanovic V: Primary non-Hodgkin lymphoma of the breast. Is it possible to avoid mastectomy? J Exp Clin Cancer Res; 2000 Jun;19(2):149-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin lymphoma of the breast. Is it possible to avoid mastectomy?
  • Primary lymphoma of the breast is a rare disease that has been estimated to represent from 0.05% to 0.53% of all malignant breast tumors and approximately 2.2% of all extranodal lymphomas.
  • The aim of this study is to review all cases of primary lymphoma of the breast at the Institute of Oncology and Radiology of Serbia from 1984 to 1996 in order to determine the incidence, patterns of clinical presentation, radiological features, histopathology, mode of therapy and outcome of the disease.
  • Ten cases of primary lymphoma of the breast have been identified during the 12-yr period, presenting 0.05% of all patients with malignant breast disease.
  • Mammography and breast echography were unable to bring a suspicion of lymphoma.
  • Histologically, 6 cases were diffuse large cell, 3 of which with features consistent with immunoblastic lymphoma; 2 were diffuse mixed cells and 2 had small lymphocytic morphology.
  • In 4 out of 5 patients, in the clinical stage corresponding to the "operable breast cancer" category, the ex tempore histological analysis could not differentiate lymphoma from cancer, so that all of them had mastectomy with axillary dissection.
  • Those corresponding to the "locally advanced breast cancer" category, escaped mastectomy and a classical biopsy was performed, anticipating eventual neoadjuvant procedures.
  • Further treatment included chemotherapy for 8 patients.
  • The rarity of this disease, and uneven treatment modalities make prognosis of breast lymphoma difficult.
  • With the limitations of available diagnostic procedures, it appears that most patients with breast lymphoma, in the stage corresponding to the "operable breast cancer" category, will unnecessarily undergo mastectomy and axillary dissection as primary treatment approach.
  • [MeSH-major] Breast Neoplasms / surgery. Lymphoma, Non-Hodgkin / surgery. Mastectomy, Radical
  • [MeSH-minor] Aged. Biopsy, Needle. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Incidence. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome


11. Chain JR, Kingdom TT: Non-Hodgkin's lymphoma of the frontal sinus presenting as osteomyelitis. Am J Otolaryngol; 2007 Jan-Feb;28(1):42-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma of the frontal sinus presenting as osteomyelitis.
  • OBJECTIVES: The aim of the study was to present a case of non-Hodgkin's lymphoma (NHL) originating in the frontal sinus that presented as osteomyelitis of the frontal bone.
  • A presumptive diagnosis of frontal sinusitis with osteomyelitis was made and prolonged oral antibiotic therapy started.
  • Computed tomography revealed a destructive process of the frontal bone with near total opacification of the frontal sinuses.
  • An exploratory external frontal sinusotomy was performed revealing an infiltrative soft tissue mass filling most of the frontal sinus.
  • Pathology of this mass revealed diffuse large B-cell lymphoma of intermediate grade.
  • The patient underwent 6 cycles of chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone; radiotherapy to the frontal bone; and central nervous system prophylaxis via intrathecal methotrexate.
  • Clinically, he fell into the Ann Arbor Stage II EA NHL category because of an isolated axillary lymph node.
  • Now, 18 months after completion of therapy he is without evidence of disease based on serial positron emission tomography and computed tomography scanning.
  • [MeSH-major] Frontal Sinus / pathology. Lymphoma, Non-Hodgkin / diagnosis. Osteomyelitis / diagnosis. Paranasal Sinus Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Osteomyelitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17162131.001).
  • [ISSN] 0196-0709
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 18
  •  go-up   go-down


12. Foss HD, Marafioti T, Stein H: [The many faces of anaplastic large cell lymphoma]. Pathologe; 2000 Mar;21(2):124-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The many faces of anaplastic large cell lymphoma].
  • [Transliterated title] Die vielen Gesichter des anaplastischen grosszelligen Lymphoms.
  • Fifteen years after their first description by one of the authors (HS) anaplastic large cell lymphoma (ALC-lymphoma, ALCL) now represents a generally accepted group of large cell lymphomas.
  • Using molecular and clinical criteria three entities of ALC-lymphoma have been identified: primary systemic anaplastic lymphoma kinase (ALK)-positive ALC-lymphoma, primary systemic ALK-negative ALC-lymphoma and primary cutaneous ALC-lymphoma.
  • The ALK expression in the primary systemic ALC-lymphoma entity is caused by chromosomal translocations, most commonly t(2;5), and can nowadays be reliably detected by immuno-histology.
  • ALK-positive ALC-lymphoma predominantly affects young male patients and if treated with chemotherapy has a favourable prognosis.
  • They show a broad morphological spectrum, with the "common type", the small cell variant and the lymphohistiocytic variant being most commonly observed.
  • The morphology and the immuno-phenotype of primary cutaneous ALC-lymphoma shows an overlap with that of lymphomatoid papulosis.
  • In contrast, large B-cell-lymphomas with anaplastic morphology are now believed not to represent an own entity but a morphologic variant of diffuse large B-cell lymphoma.
  • Malignant lymphomas with morphological features of both Hodgkin- and ALC-lymphoma have formerly been classified as ALCL Hodgkin-like.
  • Recent immuno-histological analysis of these cases however suggests that ALCL Hodgkin-like does not represent an own lymphoma entity.
  • Most of these cases are likely to be examples of tumor cell rich classical Hodgkin lymphoma, while a minority of these cases appear to fall either into the category of ALK-positive or ALK-negative ALC-lymphoma.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / classification. Lymphoma, Large B-Cell, Diffuse / pathology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10840818.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 32
  •  go-up   go-down


13. Hines-Thomas M, Kaste SC, Hudson MM, Howard SC, Liu WA, Wu J, Kun LE, Shulkin BL, Krasin MJ, Metzger ML: Comparison of gallium and PET scans at diagnosis and follow-up of pediatric patients with Hodgkin lymphoma. Pediatr Blood Cancer; 2008 Aug;51(2):198-203
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of gallium and PET scans at diagnosis and follow-up of pediatric patients with Hodgkin lymphoma.
  • BACKGROUND: Positron emission tomography (PET) and gallium scans facilitate diagnosis and staging, evaluation of response to therapy, and monitoring for relapse in Hodgkin lymphoma (HL), but have not been compared in pediatric HL.
  • PROCEDURE: We performed concurrent PET and gallium scans on 44 pediatric HL patients at diagnosis, early response, off chemotherapy, and off-therapy evaluations.
  • PET and gallium scans were compared to each other and to computed tomography (CT) alone to determine whether either modality led to a change in stage or modified the results of the early response evaluation, which was used to determine the radiation dose.
  • RESULTS: PET upstaged four patients at diagnosis (2 from stage I to II, one II to III, and one III to IV), but did not lead to a change in therapy in any of them.
  • It changed response category in two patients at early response evaluation, leading to a change in radiation dose for 1 patient (25.5 Gy instead of 15 Gy to the spleen).
  • Gallium did not change the stage of treatment for any patient.
  • The negative predictive values for eventual lymphoma relapse of PET and gallium scans at off therapy were 89% and 83%, respectively; the positive predictive value of PET at off therapy is 29%.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18428430.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R25 CA023944; United States / NCI NIH HHS / CA / 5 R25 CA23944
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gallium Radioisotopes
  •  go-up   go-down


14. Herbertson RA, Evans LS, Hutchinson J, Horsman J, Hancock BW: Poor outcome in adolescents with high-risk Hodgkin lymphoma. Int J Oncol; 2008 Jul;33(1):145-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poor outcome in adolescents with high-risk Hodgkin lymphoma.
  • This retrospective study looks at the differences between adolescents (15-19 years) and young adults (20-25 years), diagnosed with Hodgkin lymphoma and treated at the same adult institution.
  • Outcome according to risk category was evaluated, and although there were no significant differences in the whole cohort, or low and intermediate-risk categories, high-risk adolescent patients had a significantly worse outcome compared to that of young adults.
  • The difference could not be explained in terms of differences in histological subtype (p=0.5), proportion of patients with bulky (p=0.6) or extranodal disease (p=0.6), initial treatment received (chemotherapy alone compared to combination therapy, p=0.2), or proportion proceeding to high-dose treatment after initial treatment failure (p=0.6).
  • There was no difference in the documented number of delays, dose reductions or episodes of non-compliance during initial treatment in the two high-risk age groups.
  • [MeSH-major] Hodgkin Disease / mortality

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18575760.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


15. Auw-Haedrich C, Coupland SE, Kapp A, Schmitt-Gräff A, Buchen R, Witschel H: Long term outcome of ocular adnexal lymphoma subtyped according to the REAL classification. Revised European and American Lymphoma. Br J Ophthalmol; 2001 Jan;85(1):63-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long term outcome of ocular adnexal lymphoma subtyped according to the REAL classification. Revised European and American Lymphoma.
  • AIM: To classify ocular adnexal lymphomas according to the Revised European and American Lymphoma (REAL) classification and to determine any correlation between clinical features or histomorphological variables with the patients' outcome.
  • METHODS: Conventional and immunohistology were performed on representative sections of 53 specimens of 46 patients with ocular adnexal lymphoma.
  • The Student's t test and log rank test were used for statistical analysis.
  • Almost all specimens represented B cell non-Hodgkin's lymphomas: extranodal marginal zone lymphoma (EMZL) (n=38), diffuse large cell B cell lymphoma (n=8), lymphoplasmocytic lymphoma/immunocytoma (n=2), mantle cell lymphoma (n=2), follicle centre lymphoma (n=1), and plasmacytoma (n=1).
  • One case of a secondary anaplastic large cell lymphoma of T cell type (T-ALCL) was diagnosed.
  • A variety of therapeutic regimens was administered, the main form of treatment being radiotherapy.
  • The average follow up time was 85 months.
  • Complete remission was achieved in 24 patients (10 after excision alone, eight after radiotherapy alone, three after combined excision and radiotherapy, one after chemotherapy alone, and two after combined radiotherapy and chemotherapy).
  • 12 patients died of causes related to lymphoma; in one patient the cause of death was unknown.
  • The stage at presentation, as well as the lymphoma malignancy category, had a significant correlation with the final course of the disease (p=0.0001 and p=0.03, respectively).
  • CONCLUSION: 67% of patients with ocular adnexal lymphoma had EMZL.
  • Primary diffuse large cell B cell lymphoma of the ocular adnexa requires at least similar therapeutic measures and regular intensive follow up.
  • [MeSH-major] Eye Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology. Plasmacytoma / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Female. Follow-Up Studies. Humans. Ki-67 Antigen / metabolism. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / therapy. Male. Middle Aged. Neoplasm Proteins / metabolism. Neoplasm Staging. Retrospective Studies. Survival Rate. Treatment Outcome. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 1996 Jan;105(1):31-7 [8561085.001]
  • [Cites] J Pathol. 1994 Aug;173(4):371-9 [7965396.001]
  • [Cites] Ophthalmology. 1998 Aug;105(8):1430-41 [9709754.001]
  • [Cites] Ann Oncol. 1998 Jul;9(7):779-81 [9739446.001]
  • [Cites] Br J Ophthalmol. 1999 Jun;83(6):742-7 [10340987.001]
  • [Cites] Ophthalmology. 1999 Nov;106(11):2109-20 [10571346.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1869-70 [5121698.001]
  • [Cites] Ophthalmology. 1979 May;86(5):948-66 [545222.001]
  • [Cites] Cancer. 1980 Aug 1;46(3):576-89 [6994870.001]
  • [Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]
  • [Cites] J Histochem Cytochem. 1984 Feb;32(2):219-29 [6198355.001]
  • [Cites] Cancer. 1984 Jun 1;53(11):2515-24 [6424928.001]
  • [Cites] Ann Ophthalmol. 1984 Nov;16(11):1046-55 [6549113.001]
  • [Cites] Ophthalmology. 1985 Oct;92(10):1311-24 [3906488.001]
  • [Cites] Blood. 1989 Nov 1;74(6):2121-9 [2804350.001]
  • [Cites] Trans Am Ophthalmol Soc. 1989;87:420-42; discussion 442-4 [2562543.001]
  • [Cites] Hum Pathol. 1990 Sep;21(9):959-73 [2394438.001]
  • [Cites] Pathol Res Pract. 1991 Jan;187(1):78-84 [2027825.001]
  • [Cites] Mayo Clin Proc. 1993 Oct;68(10):1003-10 [8412350.001]
  • [Cites] Ophthalmology. 1995 Dec;102(12):1994-2006 [9098307.001]
  • (PMID = 11133714.001).
  • [ISSN] 0007-1161
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC1723704
  •  go-up   go-down


16. Ferreri AJ, Montalbán C: Primary diffuse large B-cell lymphoma of the stomach. Crit Rev Oncol Hematol; 2007 Jul;63(1):65-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary diffuse large B-cell lymphoma of the stomach.
  • The stomach is the extranodal site most commonly involved by non-Hodgkin lymphomas.
  • Diffuse large B-cell lymphoma is the most common histotype category arising in this organ.
  • This is an aggressive lymphoma usually presenting as limited disease, being associated or not to Helicobacter pylori infection and mucosa-associated lymphoid tissue-type areas.
  • It occurs more frequently in males with a median age ranging between 50 and 60 years.
  • With an adequate therapeutic strategy, its prognosis is good, with a 5-year overall survival near to 90%.
  • Conservative treatment with anthracycline-containing chemotherapy, followed or not by involved-field radiotherapy has replaced gastrectomy as standard approach against this malignancy.
  • Several questions on the best treatment remain unanswered.
  • Among others, the role of rituximab, consolidation radiotherapy as well as of more conservative approaches like H. pylori-eradicating antibiotic therapy should be better defined.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell. Lymphoma, Large B-Cell, Diffuse. Stomach Neoplasms
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Female. Helicobacter Infections / complications. Helicobacter Infections / drug therapy. Helicobacter pylori / pathogenicity. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Rituximab. Sex Factors

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17339119.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 60
  •  go-up   go-down


17. Zebrack BJ, Zeltzer LK, Whitton J, Mertens AC, Odom L, Berkow R, Robison LL: Psychological outcomes in long-term survivors of childhood leukemia, Hodgkin's disease, and non-Hodgkin's lymphoma: a report from the Childhood Cancer Survivor Study. Pediatrics; 2002 Jul;110(1 Pt 1):42-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Psychological outcomes in long-term survivors of childhood leukemia, Hodgkin's disease, and non-Hodgkin's lymphoma: a report from the Childhood Cancer Survivor Study.
  • OBJECTIVE: To evaluate and compare psychological outcomes in long-term survivors of pediatric leukemia, Hodgkin's disease, and non-Hodgkin's lymphoma and sibling controls.
  • METHODS: Adult survivors of childhood leukemia, Hodgkin's disease, and non-Hodgkin's lymphoma (N = 5736) and sibling controls (N = 2565) were administered a long-term follow-up questionnaire allowing assessment of symptoms associated with depression and somatic distress.
  • Among leukemia, Hodgkin's disease, and non-Hodgkin's lymphoma survivors, in addition to gender and SES, the only treatment variable that predicted scores indicating depressive symptomatology was exposure to intensive chemotherapy.
  • Exposure to intensive chemotherapy also predicted scores indicative of somatic distress symptoms.
  • No other medical variables, including diagnostic category, age at diagnosis, time since diagnosis, and duration of treatment, predicted symptomatic scores for depression and somatic distress.
  • CONCLUSIONS: This large, sibling-controlled, multisite study of young adult survivors of childhood leukemia, Hodgkin's disease, and non-Hodgkin's lymphoma found that survivors had significant increased risk for reporting symptoms of depression and somatic distress and that intensive chemotherapy added to this risk.
  • The ability of SES, gender, and treatment-related variables to predict psychological symptoms in this cohort of childhood survivors and sibling controls calls for future research into varied biological and psychosocial pathways by which cancer influences future psychosocial functioning.
  • [MeSH-major] Depressive Disorder / diagnosis. Hodgkin Disease / psychology. Leukemia / psychology. Lymphoma, Non-Hodgkin / psychology. Somatoform Disorders / diagnosis. Survivors / psychology

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pediatrics. 2003 Dec;112(6 Pt 1):1454-5; author reply 1454-5 [14654630.001]
  • (PMID = 12093945.001).
  • [ISSN] 1098-4275
  • [Journal-full-title] Pediatrics
  • [ISO-abbreviation] Pediatrics
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / F32CA89875-01; United States / NCI NIH HHS / CA / U24 CA55727
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


18. Sissolak G, Juritz J, Sissolak D, Wood L, Jacobs P: Lymphoma--emerging realities in sub-Saharan Africa. Transfus Apher Sci; 2010 Apr;42(2):141-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma--emerging realities in sub-Saharan Africa.
  • Substantial geographical differences exist for Hodgkin and other lymphoproliferative disorders with these having previously been documented in a report from the lymphoma reclassification project.
  • Median age was 55.2 years 61% were males, 10% had Hodgkin lymphoma and, overall, constitutional symptoms were present in 20%.
  • Prior to referral 19% had received chemotherapy and a further 20% some form of irradiation.
  • Median survival in hairy cell leukaemia (n=14), chronic lymphocytic leukaemia-small lymphocytic lymphoma (n=103), Hodgkin (n=41) and follicular lymphoma (n=59) was not reached at the time of analysis and exceeded 36 months.
  • Adverse factors were constitutional symptoms, prior treatment with chemotherapy, intermediate or high-risk scores as defined by the international prognostic index, histologic grading and certain anatomical sites of primary tumour.
  • In contrast gender, staging by Rye or Rai classification, retroviral infection and prior treatment with radiotherapy were without effect.
  • Overall survival at 3 years in each category was compared to the curve for the entire cohort and was 100% in hairy cell leukaemia receiving two chlorodeoxyadenosine and greater than 88% in Hodgkin lymphoma treated according to the German study group protocols (p=0.0004).
  • Corresponding figures for chronic lymphocytic leukaemia-small lymphocytic lymphoma were 82% (p=0.0006), follicular lymphoma 71% (p=0.060), peripheral T-cell lymphoma 43% (p=0.0156), diffuse large B-cell lymphoma 39% (p<0.0001), aggressive tumours 25% (p=0.0002) and for the indolent categories including mantle cell, splenic and extra nodal marginal cell lymphomas 22% (p=0.2023).
  • Outcome argues in favour of patient management by a multidisciplinary team implicit in which are standardised protocols for diagnosis, staging and treatment.
  • [MeSH-major] Lymphoma

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010. Published by Elsevier Ltd.
  • (PMID = 20149748.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


19. Brusamolino E, Bacigalupo A, Barosi G, Biti G, Gobbi PG, Levis A, Marchetti M, Santoro A, Zinzani PL, Tura S: Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up. Haematologica; 2009 Apr;94(4):550-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up.
  • The Italian Society of Hematology (SIE), the Italian Society of Experimental Haematology (SIES) and the Italian Group for Bone Marrow Transplantation (GITMO) commissioned a project to develop practice guidelines for the initial work-up, therapy and follow-up of classical Hodgkin's lymphoma.
  • Key questions to the clinical evaluation and treatment of this disease were formulated by an Advisory Committee, discussed and approved by an Expert Panel (EP) composed of senior hematologists and one radiotherapist.
  • The EP decided that the target domain of the guidelines should include only classical Hodgkin's lymphoma, as defined by the WHO classification, and exclude lymphocyte predominant histology.
  • Distinct recommendations were produced for initial work-up, first-line therapy of early and advanced stage disease, monitoring procedures and salvage therapy, including hemopoietic stem cell transplant.
  • Pre-treatment volumetric CT scan of the neck, thorax, abdomen, and pelvis is mandatory, while FDG-PET is recommended.
  • As to the therapy of early stage disease, a combined modality approach is still recommended with ABVD followed by involved-field radiotherapy; the number of courses of ABVD will depend on the patient risk category (favorable or unfavorable).
  • Full-term chemotherapy with ABVD is recommended in advanced stage disease; adjuvant radiotherapy in patients without initial bulk who achieved a complete remission is not recommended.
  • In the elderly, chemotherapy regimens more intensive than ABVD are not recommended.
  • Relapsed or refractory patients should receive high-dose chemotherapy and autologous hemopoietic stem cells transplant.
  • All fertile patients should be informed of the possible effects of therapy on gonadal function and fertility preservation measures should be taken before the initiation of therapy.
  • [MeSH-major] Bone Marrow Transplantation. Hodgkin Disease / therapy
  • [MeSH-minor] Classification. Humans. Italy. Positron-Emission Tomography / methods. Salvage Therapy / methods. Societies, Medical. World Health Organization

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2007 Feb;18(2):357-63 [17071932.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):579-86 [17242396.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):571-8 [17242397.001]
  • [Cites] Haematologica. 2007 Jun;92(6):771-7 [17550849.001]
  • [Cites] J Clin Oncol. 2007 Jul 1;25(19):2825-32 [17515571.001]
  • [Cites] J Clin Oncol. 2007 Aug 10;25(23):3495-502 [17606976.001]
  • [Cites] J Clin Oncol. 2007 Aug 10;25(23):3511-7 [17646668.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3746-52 [17646666.001]
  • [Cites] N Engl J Med. 2002 May 2;346(18):1417-8 [11986425.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 1:133-7 [12078895.001]
  • [Cites] Lancet. 2002 Jun 15;359(9323):2065-71 [12086759.001]
  • [Cites] Ann Oncol. 2002 Oct;13(10):1628-35 [12377653.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1638-45 [9193364.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):818-29 [9508162.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1506-14 [9819449.001]
  • [Cites] Hum Reprod. 1998 Nov;13(11):3256-61 [9853891.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):534-45 [10080597.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):730-4 [10080622.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):222-9 [10458237.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3101-9 [10506605.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3483-9 [15315964.001]
  • [Cites] Ann Oncol. 2004 Dec;15(12):1798-804 [15550585.001]
  • [Cites] Ann Oncol. 2005 Jan;16(1):124-31 [15598949.001]
  • [Cites] Bone Marrow Transplant. 2005 May;35(10):943-51 [15806128.001]
  • [Cites] Lancet. 2005 Jun 4-10;365(9475):1934-41 [15936420.001]
  • [Cites] Eur J Haematol Suppl. 2005 Jul;(66):135-40 [16007882.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4634-42 [15837968.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5052-60 [15955904.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1473-8 [15870180.001]
  • [Cites] Haematologica. 2005 Sep;90(9):1236-57 [16154848.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6400-8 [16155026.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7614-20 [16186594.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7555-64 [16234521.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9198-207 [16172458.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9208-18 [16314615.001]
  • [Cites] Blood. 2006 Jan 1;107(1):52-9 [16150944.001]
  • [Cites] Br J Haematol. 2002 Nov;119(2):432-40 [12406082.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4310-6 [12393626.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):607-14 [12586796.001]
  • [Cites] Hum Reprod. 2003 Apr;18(4):796-801 [12660273.001]
  • [Cites] Haematologica. 2003 Apr;88(4):438-44 [12681971.001]
  • [Cites] Bone Marrow Transplant. 2003 Apr;31(8):667-78 [12692607.001]
  • [Cites] N Engl J Med. 2003 Jun 12;348(24):2386-95 [12802024.001]
  • [Cites] N Engl J Med. 2003 Jun 12;348(24):2396-406 [12802025.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3431-9 [12885835.001]
  • [Cites] J Clin Oncol. 2003 Oct 1;21(19):3601-8 [12913100.001]
  • [Cites] Cancer. 2003 Dec 1;98(11):2393-401 [14635074.001]
  • [Cites] Ann Oncol. 2004 Jan;15(1):123-8 [14679131.001]
  • [Cites] Blood. 2004 Jan 1;103(1):58-66 [12907440.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2835-41 [15199092.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3139-48 [15284266.001]
  • [Cites] Ann Intern Med. 1980 May;92(5):587-95 [6892984.001]
  • [Cites] Blood. 1981 Oct;58(4):849-51 [7272513.001]
  • [Cites] N Engl J Med. 1992 Nov 19;327(21):1478-84 [1383821.001]
  • [Cites] Lancet. 1993 Apr 24;341(8852):1051-4 [8096958.001]
  • [Cites] J Clin Oncol. 1993 May;11(5):925-30 [8487056.001]
  • [Cites] JAMA. 1993 Oct 27;270(16):1949-55 [8411552.001]
  • [Cites] J Clin Oncol. 1993 Dec;11(12):2342-50 [8246023.001]
  • [Cites] J Clin Oncol. 1994 Feb;12(2):279-87 [7509381.001]
  • [Cites] Blood. 1994 Mar 1;83(5):1193-9 [8118023.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1421-30 [8622055.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):572-8 [8636773.001]
  • [Cites] Cancer. 1999 Nov 1;86(9):1812-7 [10547555.001]
  • [Cites] Cancer. 1999 Nov 15;86(10):2138-42 [10570443.001]
  • [Cites] N Engl J Med. 2000 Jun 22;342(25):1919 [10877641.001]
  • [Cites] Blood. 2001 Feb 1;97(3):616-23 [11157476.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1395-404 [11230484.001]
  • [Cites] J Clin Oncol. 2001 Nov 15;19(22):4238-44 [11709567.001]
  • [Cites] J Clin Oncol. 2001 Dec 1;19(23):4314-21 [11731514.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):221-30 [11773173.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):630-7 [11821442.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1087-93 [11844834.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1297-305 [8648387.001]
  • [Cites] Hum Reprod. 1996 Aug;11(8):1620-6 [8921104.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):528-34 [9053474.001]
  • [Cites] Blood. 1997 Feb 1;89(3):814-22 [9028312.001]
  • [Cites] Haematologica. 2006 Jan;91(1):96-103 [16434377.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Feb;12(2):172-83 [16443515.001]
  • [Cites] Haematologica. 2006 Apr;91(4):522-9 [16585017.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4636-42 [16478882.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2917-31 [16651642.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3128-35 [16754934.001]
  • [Cites] Leuk Lymphoma. 2006 Aug;47(8):1518-22 [16966262.001]
  • [Cites] Clin Cancer Res. 2006 Nov 1;12(21):6487-93 [17085663.001]
  • [Cites] Haematologica. 2007 Jan;92(1):35-41 [17229633.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2316-23 [17597807.001]
  • [Cites] N Engl J Med. 2007 Nov 8;357(19):1916-27 [17989384.001]
  • [Cites] Blood. 2008 Jan 1;111(1):71-6 [17890456.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):455-62 [18086796.001]
  • [Cites] Ann Oncol. 2008 May;19 Suppl 2:ii65-6 [18456773.001]
  • [Cites] Haematologica. 2008 Sep;93(9):1364-71 [18603558.001]
  • [Cites] Haematologica. 2005 Dec;90(12):1725-6 [16330461.001]
  • [Cites] Ann Intern Med. 1986 Jun;104(6):739-46 [2422994.001]
  • [Cites] J Clin Oncol. 1986 Sep;4(9):1295-306 [3528400.001]
  • [Cites] J Clin Oncol. 1987 Jan;5(1):27-37 [2433409.001]
  • [Cites] Cancer Chemother Pharmacol. 1987;19(2):159-62 [3105906.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1630-6 [2809679.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Sep;19(3):707-14 [2211219.001]
  • [Cites] J Clin Oncol. 1991 Jun;9(6):947-53 [2033430.001]
  • [Cites] J Clin Oncol. 1992 Feb;10(2):210-8 [1732422.001]
  • (PMID = 19278966.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2663619
  •  go-up   go-down


20. Madrigal B, Arenal JJ, Torres A, Peñarrubia MJ, Vara A, Ruiz M, Hernández A, Enríquez P: [Jejunal mucormycosis in a patient with Hodgkin's lymphoma]. Rev Esp Enferm Dig; 2008 Aug;100(8):507-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Jejunal mucormycosis in a patient with Hodgkin's lymphoma].
  • [Transliterated title] Mucormicosis yeyunal en paciente con linfoma de Hodgkin.
  • We report a case of intestinal mucormycosis in a 46-year-old male diagnosed with classical Hodgkin's disease, IV-B stage.
  • During the first phase of chemotherapy he had a massive digestive bleeding event secondary to a jejunal ulcer, and zygomicosis mucor-type was diagnosed by endoscopic biopsy.
  • The patient was treated with antifungal drugs and surgical resection of the intestine involved.
  • After one year of follow-up the patient is doing well, and his lymphoma is on remission.
  • To our best knowledge this is the second case of intestinal mucormycosis in a patient with Hodgkin's lymphoma reported in the medical literature.
  • [MeSH-major] Hodgkin Disease / complications. Jejunal Diseases / complications. Jejunal Diseases / microbiology. Mucormycosis / complications

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Small Intestine Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18942905.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


21. Delgado M, Razola P, Abós MD, Martí JL, Murillo L, García F, Prats E, Banzo J: [Can 67Ga citrate predict the efficacy of chemotherapy early in Hodgkin's lymphoma?]. Rev Esp Med Nucl; 2001 Feb;20(1):40-1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Can 67Ga citrate predict the efficacy of chemotherapy early in Hodgkin's lymphoma?].
  • [Transliterated title] "¿Puede el citrato de 67Ga predecir de forma precoz la eficacia de la quimioterapia en el linfoma de Hodgkin?"
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Citrates. Gallium. Hodgkin Disease / radionuclide imaging. Radiopharmaceuticals
  • [MeSH-minor] Adolescent. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Methotrexate / administration & dosage. Prednisone / administration & dosage. Procarbazine / administration & dosage. Radiotherapy, Adjuvant. Radiotherapy, High-Energy. Remission Induction. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. GALLIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11181330.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Citrates; 0 / Radiopharmaceuticals; 27905-02-8 / gallium citrate; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; CH46OC8YV4 / Gallium; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; COMP protocol; DVPP protocol
  •  go-up   go-down


22. Zodelava M, Betaneli M, Tsartsidze E, Kharabadze M: Prognostic factors in indolent and aggressive lymphomas and its influence on disease outcome. Georgian Med News; 2009 Feb;(167):32-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of the study was to determine the prognostic significance of clinical, laboratory and immunological parameters in indolent and aggressive lymphomas, and to evaluate overall survival in different risk category patients.
  • Efficacy of treatment was studied in indolent lymphomas, which revealed that in case of one or two unfavorable prognostic factors treatment response is high (82-100%), in case of three factors possibility of remission decreases (56%), in regards to four or five unfavorable factors remission rate is the lowest (40%).
  • Analysis of results showed that T-cell phenotype strongly influence the survival of patients with diagnosis of aggressive non-Hodgkin's lymphomas, patients' survival is lower in T-cell lymphomas 7.6 month compared with 17.3 month for B-cell lymphomas.
  • In patients with diagnosis of stage III or IV aggressive lymphomas, three or more unfavorable prognostic factors and T-cell phenotype detects patient which are refractory to the standard chemotherapy schedules.
  • In diffuse large B-cell lymphomas according to the CD10 expression (which was used as an unfavorable prognostic factor in high and high intermediate risk groups) and quantity of the unfavorable prognostic factors identified patients which were primary refractory to standard treatment regimens.
  • In addition we could conclude that in indolent and aggressive lymphomas clinical, laboratory and immunological parameters could be used to identify patients which are primary refractory to standard therapies of treatment.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease Progression. Drug Resistance, Neoplasm. Humans. Middle Aged. Neoplasm Staging. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19276466.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Georgia (Republic)
  •  go-up   go-down


23. Wood L, Robinson R, Gavine L, Juritz J, Jacobs P: A single unit lymphoma experience: outcome in a Cape Town academic centre. Transfus Apher Sci; 2007 Aug;37(1):93-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A single unit lymphoma experience: outcome in a Cape Town academic centre.
  • To document outcome in Hodgkin and other lymphomas from a privately based academic centre the clinical records from 253 consecutive referrals were analysed.
  • Diagnosis was according to World Health Organization criteria, prognosis assigned by the international index and therapy risk-stratified with results subject to appropriate statistical methodology.
  • Constitutional symptoms were present in 22%; a quarter had previous chemotherapy and a third some form of irradiation prior to referral.
  • Fifty-seven percent were stage I or II and 21% had nodal disease above and below the diaphragm whilst in the remainder cells were present in the circulation and this included the subset of chronic lymphocytic leukaemia -- small lymphocytic lymphoma.
  • Further adverse factors included any prior treatment, intermediate or high-grade histopathology, risk factors defined by the International Prognostic Index as well as late Rai stages.
  • Analysed by disease category Hodgkin lymphoma (n=17) when managed according to the German Study Group protocols and hairy cell leukaemia (n=10) treated with two chlorodeoxyadenosine -- both had a stable plateau in excess of 90%.
  • Curves for the aggressive or diffuse large B-cell lymphoma (n=44) fell initially to 48%, but relapse continued in stages III and IV to the current level of 18% when receiving cyclophosphamide, hydroxydaunorubicin, vincristine and prednisone on the 21-day schedule.
  • Chronic lymphocytic leukaemia -- small lymphocytic lymphoma (n=58) were initially given pulsed chlorambucil and sustained response was over 90% with low bulk, but declined to reach 30% as prognostic score rose.
  • It is concluded that precise diagnosis, accurate staging and therapy on standardised risk-stratified programmes, delivered uniformly by a single multidisciplinary group, creates the all-important centre effect; matching figures are unlikely to apply outside these disciplined circumstances.
  • It follows that late referral and prior therapy will adversely affect performance status and compromise life span: These alternative approaches are inappropriate and strongly discouraged.
  • [MeSH-major] Hospitals, Private. Leukemia, Lymphocytic, Chronic, B-Cell / mortality. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Lymphoma / mortality. Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols. Child. Cohort Studies. Developing Countries. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Risk Factors. South Africa. Survival Rate

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17931976.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


24. Nishioka T, Tsuchiya K, Nishioka S, Kitahara T, Ohmori K, Homma A, Aoyma H, Shindoh M, Shirato H: Pilot study of modified version of CHOP plus radiotherapy for early-stage aggressive non-Hodgkin's lymphoma of the head and neck. Int J Radiat Oncol Biol Phys; 2004 Nov 1;60(3):847-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot study of modified version of CHOP plus radiotherapy for early-stage aggressive non-Hodgkin's lymphoma of the head and neck.
  • PURPOSE: To evaluate the safety and efficacy of a modified version of cyclophosphamide, doxorubicin, vincristine, prednisone (pirarubicin, cyclophosphamide, vincristine, and prednisone [THP-COP]) plus radiotherapy for early-stage aggressive non-Hodgkin's lymphoma of the head and neck.
  • METHODS AND MATERIALS: Between December 1993 and December 1999, 41 patients with early-stage non-Hodgkin's lymphoma with intermediate-grade histologic features were enrolled in our study.
  • All patients were in the low-risk category according to the International Prognostic Index.
  • Chemotherapy consisted of 40 mg/m(2) i.v. pirarubicin (THP-Adriamycin), 750 mg/m(2) i.v. cyclophosphamide, and 1.0 mg/m(2) i.v. vincristine, on Day 1 and 40 mg/m(2) p.o. prednisone on Days 1-5.
  • The combination chemotherapy was given twice at a 14-day interval.
  • Radiotherapy was given to involved areas at a fraction size of 2.0-2.5 Gy up to a total of 40 Gy within 4-5 weeks.
  • Grade 4 neutropenia was seen in 12% of patients; however, 93% of patients (38 of 41) received chemotherapy as scheduled with the support of granulocyte colony-stimulating factor.
  • CONCLUSION: Biweekly THP-COP plus radiotherapy is feasible and effective for Stage I-II low-risk non-Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / radiotherapy. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Female. Humans. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy. Male. Middle Aged. Neoplasm Staging. Pilot Projects. Prednisone / administration & dosage. Recurrence. Survival Rate. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15465202.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol, modified
  •  go-up   go-down


25. Thiessard F, Morlat P, Marimoutou C, Labouyrie E, Ragnaud JM, Pellegrin JL, Dupon M, Dabis F: Prognostic factors after non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus: Aquitaine Cohort, France, 1986-1997. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA). Cancer; 2000 Apr 1;88(7):1696-702
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors after non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus: Aquitaine Cohort, France, 1986-1997. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA).
  • BACKGROUND: The prognosis for survival of patients infected with the human immunodeficiency virus (HIV) who develop non-Hodgkin lymphoma (NHL) usually is considered to be poor.
  • To the authors' knowledge the impact of highly active antiretroviral therapy, recently introduced in HIV disease case management, has not yet been studied in such circumstances.
  • The median proportional hazards cell count at the time of diagnosis of NHL was 112/mm(3).
  • Approximately 73% of patients received a specific NHL chemotherapy.
  • During follow-up, 44% were treated with nucleoside reverse transcriptase inhibitors (NRTIs) alone and 18% with triple therapy including a protease inhibitor (PI).
  • In multivariate analysis, after adjusting for age, year of NHL diagnosis, histologic type, medical center, and transmission category, the following factors recorded at the time of diagnosis of NHL were indicative of an increasing risk of death: CD4+ count </= 50/mm(3) (relative hazard [RH: 2.4, 95% confidence interval [95% CI], 1.2-4.7), hemoglobin </= 10 g/dL (RH: 2.1, 95% CI, 1.1-4.0), and Ann Arbor Stage IV (RH: 2.0, 95% CI, 1.2-3.6).
  • Antiretroviral therapy after the diagnosis of NHL was associated with survival: NRTIs (RH: 0.27, 95% CI, 0.13-0.53) and NRTIs plus PI (RH: 0.08, 95% CI, 0.03-0.21).
  • CONCLUSIONS: Although recently introduced and prescribed, antiretroviral therapy including PIs already has improved the survival of HIV-infected patients with NHL significantly.
  • [MeSH-major] HIV Infections / complications. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / virology
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Cohort Studies. Disease-Free Survival. Female. HIV Seropositivity / complications. Humans. Male. Middle Aged. Prognosis. Protease Inhibitors / therapeutic use. Reverse Transcriptase Inhibitors / therapeutic use. Time Factors


26. Boleti E, Johnson PW: Primary mediastinal B-cell lymphoma. Hematol Oncol; 2007 Dec;25(4):157-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mediastinal B-cell lymphoma.
  • Primary mediastinal B-cell lymphoma (PMBCL) is a sub-type of the heterogeneous diffuse large B-cell lymphoma category, and comprises approximately 5% of all non-Hodgkin's lymphomas (NHL).
  • Gene expression profiling has suggested a partial overlap with nodular sclerosing Hodgkin lymphoma (HL), with which it shares some clinical features.
  • There is uncertainty as to whether weekly alternating chemotherapy regimens may be more effective than CHOP, whether consolidation radiotherapy (RT) to the mediastinum is always required, whether PET scanning can be used to determine this, and whether the use of rituximab as part of initial therapy will change the answers to these questions.
  • The International Extranodal Lymphoma Study Group (IELSG) 26 clinicopathologic study of PMBCL, which has recently opened, represents a first attempt to gather data prospectively on some of these issues.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Mediastinal Neoplasms / pathology
  • [MeSH-minor] Cytogenetic Analysis. Disease Management. Gene Expression Profiling. Humans. Immunophenotyping. Lymphoma, Large B-Cell, Diffuse

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 John Wiley & Sons, Ltd
  • (PMID = 17575573.001).
  • [ISSN] 0278-0232
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 54
  •  go-up   go-down






Advertisement